ESC 365 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes mellitus: a systematic review and meta-analysis with over 10,000 patients

ESC Premium Access

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes mellitus: a systematic review and meta-analysis with over 10,000 patients

Session: Cholesterol-lowering therapy for primary and secondary prevention

Topic: Lipids (Epidemiology and Prevention)

Speaker: Doctor L. Carvalho (Brasilia, BR)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Luiz Sergio Carvalho

Catholic University of Brasilia, Brasilia (Brazil)

1 presentation

0 follower

4 more presentations in this session

State of the Art: cholesterol-lowering therapy for primary and secondary prevention

Speaker: Doctor J. Robinson (Iowa, US)

Effect of the magnitude of LDL lowering on the incidence of cataract among patients treated with statins or PCSK9 antibodies

Speaker: Doctor J. Kostis (New Brunswick, US)

Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients

Speaker: Doctor A. Endo (Izumo, JP)

Lipid-lowering therapy in primary prevention: where will we be 10 years from now

Speaker: Professor A. Catapano (Milan, IT)

Access the full session

Cholesterol-lowering therapy for primary and secondary prevention

Speakers: Doctor L. Carvalho, Doctor J. Robinson, Doctor J. Kostis, Doctor A. Endo, Professor A. Catapano

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources